Deoxyspergualin, a novel immunosuppressant, markedly inhibits human mixed lymphocyte reaction and cytotoxic T-lymphocyte activity in vitro

Hideji Fujii, Teruyo Takada, Kyuichi Nemoto, Fuminori Abe, Akio Fujii, James E Talmadge, Tomio Takeuchi

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Deoxyspergualin (DSG) has demonstrated potent immunosuppressive activities in vivo. However, because of its lability in culture medium, the mechanism of activity has not yet been identified in vitro. In this study, a more stable analogue, deoxymethylspergualin (MeDSG), was used to investigate the in vitro immunosuppressive activity of DSG. MeDSG suppressed both human mixed lymphocyte reaction (MLR) and cytotoxi T-lymphocyte (CTL) activity at doses greater than 0.1 μg/ml in vitro. In kinetics studies, MeDSG was found to suppress a MLR when added on day 3 of a 7 day MLR incubation but cyclosporin A (CYA) suppressed a MLR only when added during the initial stage of a MLR (i.e. on day 1). In studies of cell surface phenotype in the MLR, MeDSG treatment decreased the numbers of CD8+ lymphocytes but those of CD4+ lymphocytes were not affected. In addition, MeDSG had no significant effect on interleukin-2 (IL-2) receptor expression or IL-2 production. These results suggest that MeDSG suppresses the T-cells which are proliferating competent cells such as cytotoxic T-cells (CD8+), but has a different mode of immunosuppressive action compared with CYA.

Original languageEnglish (US)
Pages (from-to)731-737
Number of pages7
JournalInternational Journal of Immunopharmacology
Volume14
Issue number4
DOIs
StatePublished - Jan 1 1992

Fingerprint

Mixed Lymphocyte Culture Test
Cytotoxic T-Lymphocytes
Immunosuppressive Agents
T-Lymphocytes
Cyclosporine
Interleukin-2 Receptors
Lymphocyte Count
Interleukin-2
Culture Media
In Vitro Techniques
gusperimus
Lymphocytes
Phenotype

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Deoxyspergualin, a novel immunosuppressant, markedly inhibits human mixed lymphocyte reaction and cytotoxic T-lymphocyte activity in vitro. / Fujii, Hideji; Takada, Teruyo; Nemoto, Kyuichi; Abe, Fuminori; Fujii, Akio; Talmadge, James E; Takeuchi, Tomio.

In: International Journal of Immunopharmacology, Vol. 14, No. 4, 01.01.1992, p. 731-737.

Research output: Contribution to journalArticle

Fujii, Hideji ; Takada, Teruyo ; Nemoto, Kyuichi ; Abe, Fuminori ; Fujii, Akio ; Talmadge, James E ; Takeuchi, Tomio. / Deoxyspergualin, a novel immunosuppressant, markedly inhibits human mixed lymphocyte reaction and cytotoxic T-lymphocyte activity in vitro. In: International Journal of Immunopharmacology. 1992 ; Vol. 14, No. 4. pp. 731-737.
@article{4794567671c4457987a7ea113c92f521,
title = "Deoxyspergualin, a novel immunosuppressant, markedly inhibits human mixed lymphocyte reaction and cytotoxic T-lymphocyte activity in vitro",
abstract = "Deoxyspergualin (DSG) has demonstrated potent immunosuppressive activities in vivo. However, because of its lability in culture medium, the mechanism of activity has not yet been identified in vitro. In this study, a more stable analogue, deoxymethylspergualin (MeDSG), was used to investigate the in vitro immunosuppressive activity of DSG. MeDSG suppressed both human mixed lymphocyte reaction (MLR) and cytotoxi T-lymphocyte (CTL) activity at doses greater than 0.1 μg/ml in vitro. In kinetics studies, MeDSG was found to suppress a MLR when added on day 3 of a 7 day MLR incubation but cyclosporin A (CYA) suppressed a MLR only when added during the initial stage of a MLR (i.e. on day 1). In studies of cell surface phenotype in the MLR, MeDSG treatment decreased the numbers of CD8+ lymphocytes but those of CD4+ lymphocytes were not affected. In addition, MeDSG had no significant effect on interleukin-2 (IL-2) receptor expression or IL-2 production. These results suggest that MeDSG suppresses the T-cells which are proliferating competent cells such as cytotoxic T-cells (CD8+), but has a different mode of immunosuppressive action compared with CYA.",
author = "Hideji Fujii and Teruyo Takada and Kyuichi Nemoto and Fuminori Abe and Akio Fujii and Talmadge, {James E} and Tomio Takeuchi",
year = "1992",
month = "1",
day = "1",
doi = "10.1016/0192-0561(92)90136-9",
language = "English (US)",
volume = "14",
pages = "731--737",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Deoxyspergualin, a novel immunosuppressant, markedly inhibits human mixed lymphocyte reaction and cytotoxic T-lymphocyte activity in vitro

AU - Fujii, Hideji

AU - Takada, Teruyo

AU - Nemoto, Kyuichi

AU - Abe, Fuminori

AU - Fujii, Akio

AU - Talmadge, James E

AU - Takeuchi, Tomio

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Deoxyspergualin (DSG) has demonstrated potent immunosuppressive activities in vivo. However, because of its lability in culture medium, the mechanism of activity has not yet been identified in vitro. In this study, a more stable analogue, deoxymethylspergualin (MeDSG), was used to investigate the in vitro immunosuppressive activity of DSG. MeDSG suppressed both human mixed lymphocyte reaction (MLR) and cytotoxi T-lymphocyte (CTL) activity at doses greater than 0.1 μg/ml in vitro. In kinetics studies, MeDSG was found to suppress a MLR when added on day 3 of a 7 day MLR incubation but cyclosporin A (CYA) suppressed a MLR only when added during the initial stage of a MLR (i.e. on day 1). In studies of cell surface phenotype in the MLR, MeDSG treatment decreased the numbers of CD8+ lymphocytes but those of CD4+ lymphocytes were not affected. In addition, MeDSG had no significant effect on interleukin-2 (IL-2) receptor expression or IL-2 production. These results suggest that MeDSG suppresses the T-cells which are proliferating competent cells such as cytotoxic T-cells (CD8+), but has a different mode of immunosuppressive action compared with CYA.

AB - Deoxyspergualin (DSG) has demonstrated potent immunosuppressive activities in vivo. However, because of its lability in culture medium, the mechanism of activity has not yet been identified in vitro. In this study, a more stable analogue, deoxymethylspergualin (MeDSG), was used to investigate the in vitro immunosuppressive activity of DSG. MeDSG suppressed both human mixed lymphocyte reaction (MLR) and cytotoxi T-lymphocyte (CTL) activity at doses greater than 0.1 μg/ml in vitro. In kinetics studies, MeDSG was found to suppress a MLR when added on day 3 of a 7 day MLR incubation but cyclosporin A (CYA) suppressed a MLR only when added during the initial stage of a MLR (i.e. on day 1). In studies of cell surface phenotype in the MLR, MeDSG treatment decreased the numbers of CD8+ lymphocytes but those of CD4+ lymphocytes were not affected. In addition, MeDSG had no significant effect on interleukin-2 (IL-2) receptor expression or IL-2 production. These results suggest that MeDSG suppresses the T-cells which are proliferating competent cells such as cytotoxic T-cells (CD8+), but has a different mode of immunosuppressive action compared with CYA.

UR - http://www.scopus.com/inward/record.url?scp=0026715906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026715906&partnerID=8YFLogxK

U2 - 10.1016/0192-0561(92)90136-9

DO - 10.1016/0192-0561(92)90136-9

M3 - Article

VL - 14

SP - 731

EP - 737

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 4

ER -